Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 19, 1997

View Archived Issues

Initial phase III results announced for pramlintide

CardioSynopsis, IHIM to co-develop novel stents

IND filed by Dusa for Levulan photodetection

Positive phase III results for Lidakol in oral herpes

Chiron Diagnostics launches breast cancer test

Alaris enters marketing agreement with Luther Medical

Three patents issued for ProLease and Medisorb

Alkermes and Janssen sign supply agreement

Generic Cardizem CD open for FDA review

Preclinical results on AVI-2221 for restenosis

Penederm launches Avita acne cream

Infanrix Hep B approved in all EU countries

ETA/ETB antagonist protects against renal insufficiency in canine model

Novopharm Biotech antibodies poised to enter phase I

Optison evaluated in phase II trials for myocardial perfusion imaging

Trega Biosciences refocuses development of HP-228

Analgesic mGluR antagonists reported in patent literature

Novel immunotoxins for the treatment of AIDS

Clobenpropit shows memory-enhancing activity in preclinical models

Tachykinin antagonist with potential as antiasthmatic

Efficacy of long-term treatment with dronabinol for AIDS-related anorexia

Antidepressant activity described for 5-HT reuptake inhibitor/5-HT antagonist

Bristol-Myers Squibb describes new taxanes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.